ENXTPA:ALCJ

Stock Analysis Report

Crossject Société Anonyme

Executive Summary

Crossject Société Anonyme develops needle-free injection systems.

Snowflake

Fundamentals

Worrying balance sheet with weak fundamentals.

Risks

  • Crossject Société Anonyme has significant price volatility in the past 3 months.
  • Crossject Société Anonyme is covered by less than 3 analysts.

Similar Companies

Share Price & News

How has Crossject Société Anonyme's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-7.5%

ENXTPA:ALCJ

0.2%

FR Medical Equipment

0.6%

FR Market


1 Year Return

-53.1%

ENXTPA:ALCJ

-14.8%

FR Medical Equipment

4.2%

FR Market

ALCJ underperformed the Medical Equipment industry which returned -14.8% over the past year.

ALCJ underperformed the Market in France which returned 4.1% over the past year.


Share holder returns

ALCJIndustryMarket
7 Day-7.5%0.2%0.6%
30 Day-9.9%-2.8%7.3%
90 Day-31.0%-6.1%4.4%
1 Year-51.6%-53.1%-13.9%-14.8%7.7%4.2%
3 Year-81.7%-82.6%23.7%21.1%48.9%34.5%
5 Year-85.0%-85.7%68.2%62.6%59.0%35.7%

Price Volatility Vs. Market

How volatile is Crossject Société Anonyme's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Crossject Société Anonyme undervalued based on future cash flows and its price relative to the stock market?

11.15x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for Crossject Société Anonyme to establish if it is available at moderate discount.

Unable to calculate intrinsic value for Crossject Société Anonyme to establish if it is available at substantial discount.


Price Based on Earnings

Crossject Société Anonyme is loss making, we can't compare its value to the Europe Medical Equipment industry average.

Crossject Société Anonyme is loss making, we can't compare the value of its earnings to the France market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Crossject Société Anonyme, we can't assess if its growth is good value.


Price Based on Value of Assets

Crossject Société Anonyme is overvalued based on assets compared to the FR Medical Equipment industry average.


Next Steps

Future Growth

How is Crossject Société Anonyme expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

13.6%

Forecasted Healthcare industry annual growth in earnings


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Unable to determine if Crossject Société Anonyme is high growth as no revenue estimate data is available.

Crossject Société Anonyme is not considered high growth as it is expected to be loss making for the next 1-3 years.

Unable to compare Crossject Société Anonyme's revenue growth to the France market average as no estimate data is available.

Unable to compare Crossject Société Anonyme's earnings growth to the France market average as it is expected to be loss making during the next 1-3 years.

Unable to compare Crossject Société Anonyme's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Crossject Société Anonyme will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Crossject Société Anonyme performed over the past 5 years?

-23.2%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Crossject Société Anonyme does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Crossject Société Anonyme's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Crossject Société Anonyme's 1-year growth to the Europe Medical Equipment industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Crossject Société Anonyme has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Crossject Société Anonyme has efficiently used its assets last year compared to the Europe Medical Equipment industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Crossject Société Anonyme improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Crossject Société Anonyme's financial position?


Financial Position Analysis

Crossject Société Anonyme is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Crossject Société Anonyme's long term commitments exceed its cash and other short term assets.


Debt to Equity History and Analysis

Crossject Société Anonyme's level of debt (391.4%) compared to net worth is high (greater than 40%).

The level of debt compared to net worth has increased over the past 5 years (130.5% vs 391.4% today).


Balance Sheet

High level of physical assets or inventory.

Debt is covered by short term assets, assets are 1.3x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Crossject Société Anonyme has less than a year of cash runway based on current free cash flow.

Crossject Société Anonyme has less than a year of cash runway if free cash flow continues to grow at historical rates of 20.7% each year.


Next Steps

Dividend

What is Crossject Société Anonyme's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Crossject Société Anonyme's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Crossject Société Anonyme's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Crossject Société Anonyme has not reported any payouts.

Unable to verify if Crossject Société Anonyme's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Crossject Société Anonyme has not reported any payouts.


Future Payout to Shareholders

No need to calculate the sustainability of Crossject Société Anonyme's dividends in 3 years as they are not expected to pay a notable one for France.


Next Steps

Management

What is the CEO of Crossject Société Anonyme's salary, the management and board of directors tenure and is there insider trading?


CEO

Patrick Alexandre 0

0yrs

Tenure

0

Mr. Patrick Alexandre co-founded Crossject Société Anonyme (f/k/a, Crossject Medical Technology) in 2001 and has been its Chairman of the Executive Board since 2012 and serves as its Chief Executive Office ...


CEO Compensation Analysis

Patrick's remuneration is lower than average for companies of similar size in France.

Patrick's compensation has been consistent with company performance over the past year, both up more than 20%.


Insider Trading

No 3 month open market individual insider trading information.


Management Team

  • Patrick Alexandre

    Co-Founder

    • Tenure: 0yrs
  • Isabelle Liebschütz

    Chief Quality & Regulatory Officer and Member of Executive Board

    • Tenure: 0yrs
  • Henri de Parseval

    COO of Engineering & Industry and Member of Executive Board

    • Tenure: 0yrs
  • Olivier Giré

    COO of Specialty Pharma & Member of Executive Board

    • Tenure: 0yrs

Board Members

  • Philippe Monnot

    Chairman of Supervisory Board

    • Tenure: 0yrs
  • Patrice Coissac (70yo)

    Member of Supervisory Board

    • Tenure: 0yrs
  • Jean-Francois Loumeau

    Member of Supervisory Board

    • Tenure: 1yrs

Company Information

Crossject Société Anonyme's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Crossject Société Anonyme
  • Ticker: ALCJ
  • Exchange: ENXTPA
  • Founded: 1997
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: €27.297m
  • Shares outstanding: 20.07m
  • Website: https://www.crossject.com

Number of Employees


Location

  • Crossject Société Anonyme
  • 6 Rue Pauline Kergomard
  • Dijon
  • Burgundy
  • 21000
  • France

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ALCJENXTPA (Euronext Paris)YesCommon StockFREURFeb 2014
74CDB (Deutsche Boerse AG)YesCommon StockDEEURFeb 2014

Biography

Crossject Société Anonyme develops needle-free injection systems. The company develops ZENEO, a needle-free, prefilled, and single-use auto-injector. Its clinical stage drugs comprise Sumatriptan, which is ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/14 22:17
End of Day Share Price2019/09/13 00:00
Earnings2018/12/31
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.